The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.
Other countries, including the UK, have set out plans for booster campaigns that include vaccine mixing, with some experts arguing this could improve efficacy. Pfizer and BioNTech had hoped to get ...
The phase 2 trial will test a 30 µg dose of the shot in around 200 adult volunteers in the US who have already received one booster dose at least 90 days before enrolment, said Pfizer.
COVID has changed so much from the first few years of the pandemic, when people got those first vaccines in 2021,” said Dr. Doug Pogue, president of BJC Medical Group.